Neurophet, a Korean medical AI company specializing in brain disease diagnosis and treatment, said it showcased the clinical applications of its advanced brain imaging AI solutions at the 63rd Annual Meeting of the American Society of Neuroradiology (ASNR 2025), held in Philadelphia from May 17 to 21.

As anti-amyloid therapies like Leqembi (ingredient: lecanemab) and Kisunla (ingredient: donanemab) gain traction in global markets, demand is rising for precision imaging tools capable of monitoring treatment response and identifying potential complications.

One such complication is amyloid-related imaging abnormalities (ARIA), a known risk in Alzheimer’s disease immunotherapy.

During the conference’s industry collaboration session, Neurophet co-CEO Been Jun-kil introduced the company’s flagship Alzheimer’s imaging software, Neurophet AQUA AD, highlighting its clinical utility in monitoring the efficacy, safety, and side effects of anti-amyloid antibody therapies.

Neurophet AQUA AD uses a quantitative analysis of MRI and PET scans to provide critical imaging insights needed during Alzheimer’s drug treatment.

“The global rollout of Alzheimer’s drugs has significantly elevated the importance of ARIA monitoring in clinical practice,” Neurophet co-CEO Been Jun-kil said. “Neurophet AQUA AD is gaining recognition as a critical imaging analysis solution, and through our participation in ASNR 2025, we aim to deepen strategic partnerships with global pharmaceutical firms and leading neurologists.”

In addition to its presentation, Neurophet showcased a broader portfolio at its exhibition booth, including Neurophet AQUA, a software for neurodegeneration imaging analysis, and Neurophet SCALE PET, a quantitative PET imaging tool.

The company stated that it would use ASNR 2025 as a launchpad to accelerate global outreach, positioning its proprietary technologies as essential tools for clinical research and treatment optimization in neurology.